Cancer immunotherapies space to witness extraordinary growth, says analyst

The market size for cancer immunotherapies is expected to grow more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, representing a rapid compound annual growth rate (CAGR) of 23.9%, according to a new study.

Business intelligence provider GBI Research’s latest report states that there are currently 2,037 products in active development in the cancer immunotherapy pipeline, equating to 37% of the entire oncology pipeline, and reflecting the strong interest in this class of therapy in product development.

Yasser Mushtaq, senior analyst for GBI Research, explains: “Although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the discovery stage to Phase I. This is indicative of the difficulty associated with progressing cancer immunotherapies from preclinical laboratory studies to clinical application in humans.”